Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1987 1
1989 1
1990 4
1991 3
1992 5
1993 10
1994 8
1995 2
1996 6
1997 7
1998 3
1999 3
2000 10
2001 2
2002 2
2003 2
2004 1
2005 5
2006 4
2007 2
2008 5
2009 8
2010 4
2011 4
2012 11
2013 13
2014 13
2015 16
2016 16
2017 20
2018 20
2019 24
2020 32
2021 46
2022 41
2023 38
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Results by year

Filters applied: . Clear all
Page 1
Clinical spectrum of high-titre GAD65 antibodies.
Budhram A, Sechi E, Flanagan EP, Dubey D, Zekeridou A, Shah SS, Gadoth A, Naddaf E, McKeon A, Pittock SJ, Zalewski NL. Budhram A, et al. J Neurol Neurosurg Psychiatry. 2021 Feb 9;92(6):645-54. doi: 10.1136/jnnp-2020-325275. Online ahead of print. J Neurol Neurosurg Psychiatry. 2021. PMID: 33563803 Free PMC article.
Sustained response to immunotherapy ranged from 5/20 (25%) in epilepsy to 32/44 (73%) in SPSD (p=0.002). Complete immunotherapy response occurred in 2/142 (1%). ...
Sustained response to immunotherapy ranged from 5/20 (25%) in epilepsy to 32/44 (73%) in SPSD (p=0.002). Complete immunotherapy respo …
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
Cacciaguerra L, Morris P, Tobin WO, Chen JJ, Banks SA, Elsbernd P, Redenbaugh V, Tillema JM, Montini F, Sechi E, Lopez-Chiriboga AS, Zalewski N, Guo Y, Rocca MA, Filippi M, Pittock SJ, Lucchinetti CF, Flanagan EP. Cacciaguerra L, et al. Neurology. 2023 Mar 28;100(13):e1418-e1432. doi: 10.1212/WNL.0000000000206820. Epub 2023 Jan 23. Neurology. 2023. PMID: 36690455 Free PMC article.
Clinical features more frequent in MOGAD than in MS included headache (18/43 [42%] vs 10/49 [20%]; p = 0.03) and somnolence (12/43 [28%] vs 2/49 [4%]; p = 0.003), the latter also more frequent than in AQP4+NMOSD (0/16 [0%]; p = 0.02). ...CSF analysis revealed …
Clinical features more frequent in MOGAD than in MS included headache (18/43 [42%] vs 10/49 [20%]; p = 0.03) and somnolence (12/43 [2 …
LGI1 antibody encephalitis: acute treatment comparisons and outcome.
Rodriguez A, Klein CJ, Sechi E, Alden E, Basso MR, Pudumjee S, Pittock SJ, McKeon A, Britton JW, Lopez-Chiriboga AS, Zekeridou A, Zalewski NL, Boeve BF, Day GS, Gadoth A, Burkholder D, Toledano M, Dubey D, Flanagan EP. Rodriguez A, et al. J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):309-315. doi: 10.1136/jnnp-2021-327302. Epub 2021 Nov 25. J Neurol Neurosurg Psychiatry. 2022. PMID: 34824144 Free PMC article.
RESULTS: Compared with intravenous immunoglobulin (IVIg) (n=21), patients treated with single-agent acute corticosteroids (intravenous, oral or both) (n=49) were more likely to experience resolution of FBDS (61% vs 7%, p=0.002) and improvements in mRS score (deltamRS score …
RESULTS: Compared with intravenous immunoglobulin (IVIg) (n=21), patients treated with single-agent acute corticosteroids (intravenous, oral …
Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
Carta S, Cobo Calvo Á, Armangué T, Saiz A, Lechner C, Rostásy K, Breu M, Baumann M, Höftberger R, Ayzenberg I, Schwake C, Sepulveda M, Martínez-Hernández E, Olivé-Cirera G, Arrambide G, Tintoré M, Bernard-Valnet R, Du Pasquier R, Brilot F, Ramanathan S, Schanda K, Gajofatto A, Ferrari S, Sechi E, Flanagan EP, Pittock SJ, Redenbaugh V, Reindl M, Marignier R, Mariotto S. Carta S, et al. Neurology. 2023 Mar 14;100(11):e1095-e1108. doi: 10.1212/WNL.0000000000201662. Epub 2022 Dec 16. Neurology. 2023. PMID: 36526426 Free PMC article.
When comparing seropositive patients according to MOG-Abs CSF status, MOG-Abs seropositive and CSF positive patients had a higher Expanded Disability Status Scale (EDSS) at nadir during the index event (median 4.5, interquartile range [IQR] 3.0-7.5 vs 3.0, IQR 2.0-6.8, p = …
When comparing seropositive patients according to MOG-Abs CSF status, MOG-Abs seropositive and CSF positive patients had a higher Expanded D …
Cerebral enhancement in MOG antibody-associated disease.
Elsbernd P, Cacciaguerra L, Krecke KN, Chen JJ, Gritsch D, Lopez-Chiriboga AS, Sechi E, Redenbaugh V, Morris PP, Carter JL, Wingerchuk DM, Tillema JM, Valencia-Sanchez C, Thakolwiboon S, Pittock SJ, Flanagan EP. Elsbernd P, et al. J Neurol Neurosurg Psychiatry. 2023 Dec 14;95(1):14-18. doi: 10.1136/jnnp-2023-331137. J Neurol Neurosurg Psychiatry. 2023. PMID: 37221051 Free PMC article.
Enhancement was often patchy/heterogeneous in MOGAD (33/59 (56%)), AQP4+NMOSD (9/14 (64%); p=0.57) and MS (16/26 (62%); p=0.63). Leptomeningeal enhancement favoured MOGAD (27/59 (46%)) over AQP4+NMOSD (1/14 (7%); p=0.01) and MS (1/26 (4%); p<0.001) …
Enhancement was often patchy/heterogeneous in MOGAD (33/59 (56%)), AQP4+NMOSD (9/14 (64%); p=0.57) and MS (16/26 (62%); p=0.63 …
Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.
Dubey D, Pittock SJ, Krecke KN, Morris PP, Sechi E, Zalewski NL, Weinshenker BG, Shosha E, Lucchinetti CF, Fryer JP, Lopez-Chiriboga AS, Chen JC, Jitprapaikulsan J, McKeon A, Gadoth A, Keegan BM, Tillema JM, Naddaf E, Patterson MC, Messacar K, Tyler KL, Flanagan EP. Dubey D, et al. JAMA Neurol. 2019 Mar 1;76(3):301-309. doi: 10.1001/jamaneurol.2018.4053. JAMA Neurol. 2019. PMID: 30575890 Free PMC article.
Longitudinally extensive T2 lesions were of similar frequency in MOG-IgG and AQP4-IgG myelitis (37 of 47 [79%] vs 28 of 34 [82%]; P = .52) but not found in MS. Multiple spinal cord lesions and conus involvement were more frequent with MOG-IgG than AQP4-IgG but not differen …
Longitudinally extensive T2 lesions were of similar frequency in MOG-IgG and AQP4-IgG myelitis (37 of 47 [79%] vs 28 of 34 [82%]; P = …
Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort.
Williams TA, Lenders JWM, Mulatero P, Burrello J, Rottenkolber M, Adolf C, Satoh F, Amar L, Quinkler M, Deinum J, Beuschlein F, Kitamoto KK, Pham U, Morimoto R, Umakoshi H, Prejbisz A, Kocjan T, Naruse M, Stowasser M, Nishikawa T, Young WF Jr, Gomez-Sanchez CE, Funder JW, Reincke M; Primary Aldosteronism Surgery Outcome (PASO) investigators. Williams TA, et al. Lancet Diabetes Endocrinol. 2017 Sep;5(9):689-699. doi: 10.1016/S2213-8587(17)30135-3. Epub 2017 May 30. Lancet Diabetes Endocrinol. 2017. PMID: 28576687 Free PMC article.
Female patients had a higher likelihood of complete clinical success (odds ratio [OR] 2.25, 95% CI 1.40-3.62; p=0.001) and clinical benefit (complete plus partial clinical success; OR 2.89, 1.49-5.59; p=0.002) than male patients. Younger patients had a higher likeli …
Female patients had a higher likelihood of complete clinical success (odds ratio [OR] 2.25, 95% CI 1.40-3.62; p=0.001) and clinical b …
Functional expression of the Spodoptera exigua chitinase to examine the virtually screened inhibitor candidates.
Zhang L, Guan Z, Pan Z, Ge H, Zhou D, Xu J, Zhang W. Zhang L, et al. Bull Entomol Res. 2019 Dec;109(6):741-751. doi: 10.1017/S0007485319000191. Epub 2019 May 22. Bull Entomol Res. 2019. PMID: 31113496
However, little is known about the chitinase of Spodoptera exigua (SeChi). In this study, based on the SeChi gene (ADI24346) identified in our laboratory, we constructed the recombinant baculovirus P-Chi for the expression of recombinant SeChi (rSeChi) …
However, little is known about the chitinase of Spodoptera exigua (SeChi). In this study, based on the SeChi gene (ADI24346) i …
Immune checkpoint inhibitor-associated central nervous system autoimmunity.
Valencia-Sanchez C, Sechi E, Dubey D, Flanagan EP, McKeon A, Pittock SJ, Zekeridou A. Valencia-Sanchez C, et al. Eur J Neurol. 2023 Aug;30(8):2418-2429. doi: 10.1111/ene.15835. Epub 2023 May 18. Eur J Neurol. 2023. PMID: 37151179
Neural autoantibodies were identified in 47%, more frequently in patients with NET (p = 0.046). ICI was discontinued in 97%; 90% received immunosuppressive treatment. ...Patients with NET and with ANNA-1 ICI-triggered CNS autoimmunity had associated peripheral nervous syst …
Neural autoantibodies were identified in 47%, more frequently in patients with NET (p = 0.046). ICI was discontinued in 97%; 90% rece …
361 results